Astellas Pharma Inc.

Pfizer’s drop of a late-stage ADC this week may signal the ADC frenzy is cooling

Plus: Lundbeck board planning to elect Dorothea Wenzel chair, and updates from PacBio and Uvax Bio

Ozempic tops list of 15 drugs whose negotiated prices will take effect in 2027

Last year’s new drug approvals by FDA reflect the continued focus on best-in-class drug development

But they agree that creating a reliable product is necessary for scalability

BioCentury’s roundup of translational innovation also features a kinase degrader for breast cancer, and half a dozen papers on product candidates

If fulfilled, CVR tied to pipeline programs would drive deal’s value even further

Two gene therapies for Duchenne muscular dystrophy advance to Phase III as a preclinical program attracts pharma acquisition

Eleven label expansions also among committee’s November recommendations

Plus: Agency approves Pfizer’s hemophilia A and B mAb, and label expansions for five products